Perez G, Ungaro B, Covelli A, Morrone G, Lombardi G, Scopacasa F, Rossi R
J Clin Endocrinol Metab. 1980 Nov;51(5):972-7. doi: 10.1210/jcem-51-5-972.
To study the mechanism of altered glucose homeostasis in hyperthyroidism, the effects of a 2-h physiological infusion of epinephrine (0.05 microgram/kg x min) or glucagon (3 ng/kg x min) on glucose kinetics and glucoregulatory hormones were determined in nine normal subjects and five untreated hyperthyroid patients. Under basal conditions, hyperthyroid patients exhibited increased glucose turnover (2.2 +/- 0.09 vs. 1.62 +/- 0.1 mg/kg x min in normals), a modest hyperglycemia, hyperglucagonemia, and normal levels of plasma insulin, cortisol, and GH. In normal subjects, epinephrine induced a sustained increase in plasma glucose (45 mg/dl), reflecting a transient 100% rise in glucose output, and a sustained 28% decrease in glucose clearance. In hyperthyroid patients, the rise in plasma glucose was significantly lower (22 mg/dl) due to a smaller but sustained increase in glucose output (45%) and the lack of a fall in glucose clearance. Plasma insulin rose to a peak 80% higher than baseline in hyperthyroid patients, whereas in normals it initially declined and then rose to levels 50% higher than basal. Plasma glucagon displayed only minor changes in both groups. Glucagon infusion induced similar increments in plasma glucagon levels in the two groups (120-150 pg/ml). Insulin, cortisol, and GH remained unchanged. Plasma glucose rose by 4 mg/dl in hyperthyroid patients and by 11 mg/dl in normal subjects. The net increments were significantly lower in the former group (P < 0.05-0.01). Glucose output increased by 40% in normals and returned to baseline by 75 min, whereas it increased by only 15% in hyperthyroid patients and remained above baseline until the end of the infusion. Glucagon had no appreciable effect on glucose clearance in either group. We conclude that hyperthyroidism is characterized by 1) increased glucose turnover and hyperglucagonemia in the basal state, 2) a reduced glucemic response to physiological infusions of epinephrine and glucagon, 3) a sustained response of glucose production to epinephrine and glucagon, and 4) the lack of epinephrine-induced suppression of glucose clearance, presumably due to an exaggerated response of insulin secretion to epinephrine.
为研究甲状腺功能亢进症时葡萄糖稳态改变的机制,我们测定了9名正常受试者和5名未经治疗的甲状腺功能亢进症患者在2小时内生理剂量输注肾上腺素(0.05微克/千克×分钟)或胰高血糖素(3纳克/千克×分钟)对葡萄糖动力学和葡萄糖调节激素的影响。在基础状态下,甲状腺功能亢进症患者的葡萄糖周转率增加(2.2±0.09对正常人为1.62±0.1毫克/千克×分钟),有轻度高血糖、高胰高血糖素血症,血浆胰岛素、皮质醇和生长激素水平正常。在正常受试者中,肾上腺素使血浆葡萄糖持续升高(45毫克/分升),反映出葡萄糖输出量瞬间增加100%,葡萄糖清除率持续下降28%。在甲状腺功能亢进症患者中,血浆葡萄糖升高幅度明显较低(22毫克/分升),原因是葡萄糖输出量虽有较小但持续的增加(45%),且葡萄糖清除率未下降。甲状腺功能亢进症患者血浆胰岛素升至峰值时比基线高80%,而在正常受试者中,胰岛素最初下降,然后升至比基础水平高50%的水平。两组血浆胰高血糖素仅有轻微变化。胰高血糖素输注使两组血浆胰高血糖素水平有相似的升高(120 - 150皮克/毫升)。胰岛素、皮质醇和生长激素保持不变。甲状腺功能亢进症患者血浆葡萄糖升高4毫克/分升,正常受试者升高11毫克/分升。前一组的净升高幅度明显较低(P < 0.05 - 0.01)。正常受试者葡萄糖输出量增加40%,并在75分钟时恢复至基线,而甲状腺功能亢进症患者仅增加15%,且在输注结束前一直高于基线。胰高血糖素对两组的葡萄糖清除率均无明显影响。我们得出结论,甲状腺功能亢进症的特征为:1)基础状态下葡萄糖周转率增加和高胰高血糖素血症;2)对肾上腺素和胰高血糖素生理输注的血糖反应降低;3)葡萄糖生成对肾上腺素和胰高血糖素的持续反应;4)缺乏肾上腺素诱导的葡萄糖清除率抑制,推测是由于胰岛素分泌对肾上腺素的反应过度。